Doximity Faces AI Threats but Strong Ecosystem Remains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 38 minutes ago
0mins
Source: NASDAQ.COM
- Market Concerns Over AI: The market's anxiety regarding AI potentially replacing Doximity's medical solutions has intensified, resulting in a staggering 56% drop in stock price in 2026, indicating investor caution about the company's future viability.
- Robust Customer Base: Doximity boasts a strong ecosystem with over 85% of U.S. physicians using its platform, and all top 20 pharmaceutical companies as advertising clients, providing a stable revenue stream for the company.
- AI Tool Adoption: In Q4, approximately 50% of active prescribers utilized AI tools within Doximity's workflow solutions, showcasing the company's potential in AI integration, although this has also led to a dip in margins.
- Investment Value Analysis: With a free cash flow multiple of just 15 times and a cash balance of $700 million, Doximity is still viewed as a top buy despite AI threats, especially as the pharmaceutical advertising sector is expected to rebound.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DOCS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DOCS
Wall Street analysts forecast DOCS stock price to rise
18 Analyst Rating
14 Buy
4 Hold
0 Sell
Strong Buy
Current: 19.390
Low
25.00
Averages
42.75
High
63.00
Current: 19.390
Low
25.00
Averages
42.75
High
63.00
About DOCS
Doximity, Inc. operates as a digital platform for United States medical professionals. The Company provides an online platform which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers primarily include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Its marketing solutions provide customers to share content on the network. Its hiring solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates. Its Workflow solutions allow customers to initiate voice and video calls with patients and manage on-call scheduling.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Doximity Shares Plunge 56% Amid AI Threat Concerns
- Stock Decline: Doximity's shares have plummeted 56% following its fourth-quarter earnings report in 2026, highlighting market concerns regarding the company's ability to survive the threats posed by the rise of AI technologies.
- Strong User Base: With over 85% of U.S. physicians using its platform, Doximity has established a massive network that attracts all of the top 20 pharmaceutical companies as advertising clients, underscoring its solid market position.
- AI Tool Adoption: In the fourth quarter, approximately 50% of Doximity's 800,000 active prescribers utilized AI tools within its workflow solutions, indicating the company's proactive integration of AI despite competitive pressures in the market.
- Optimistic Investment Outlook: Despite rising costs during its
See More
Doximity Faces AI Threats but Strong Ecosystem Remains
- Market Concerns Over AI: The market's anxiety regarding AI potentially replacing Doximity's medical solutions has intensified, resulting in a staggering 56% drop in stock price in 2026, indicating investor caution about the company's future viability.
- Robust Customer Base: Doximity boasts a strong ecosystem with over 85% of U.S. physicians using its platform, and all top 20 pharmaceutical companies as advertising clients, providing a stable revenue stream for the company.
- AI Tool Adoption: In Q4, approximately 50% of active prescribers utilized AI tools within Doximity's workflow solutions, showcasing the company's potential in AI integration, although this has also led to a dip in margins.
- Investment Value Analysis: With a free cash flow multiple of just 15 times and a cash balance of $700 million, Doximity is still viewed as a top buy despite AI threats, especially as the pharmaceutical advertising sector is expected to rebound.
See More
Doximity Faces Securities Fraud Investigation
- Financial Performance Warning: Doximity announced its Q4 and FY 2026 results, projecting full-year revenue between $664 million and $676 million, falling short of market expectations of $687.04 million, indicating growth challenges for the company.
- AI Cost Impact: Management highlighted that AI compute costs negatively affected gross margins, with the VP of investor relations mentioning this issue, while CEO Jeff Tangney warned that increased AI investments would pressure near-term profitability, reflecting the risks associated with tech investments.
- Significant Stock Decline: Following the earnings report, Doximity's stock price plummeted by $5.38, or 23%, closing at $18.01 per share on May 14, 2026, signaling market concerns regarding the company's outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Doximity and its executives engaged in securities fraud or other unlawful practices, advising investors to contact the firm for more information, indicating potential legal risks for the company.
See More
Bitcoin-Linked Stocks Rise as Starbucks Gets Upgrade
- Bitcoin-Linked Stocks Rise: Bitcoin rose 2% as the Senate Banking Committee discussed a regulatory framework for cryptocurrencies, with Coinbase shares jumping nearly 9%, indicating growing market confidence that could drive future growth for related companies.
- Starbucks Upgrade: TD Cowen upgraded Starbucks from hold to buy, raising its price target from $106 to $120, with analysts noting multiple positive sales drivers in a strong market backdrop, suggesting improved performance ahead.
- Ford Stock Surge: Ford shares rose 7%, adding to a 13% gain from Wednesday, as Morgan Stanley highlighted its energy storage business and partnership with CATL, projecting a $3 billion incremental revenue opportunity for Ford's Model e segment.
- Applied Materials Earnings Outlook: Applied Materials saw a 2% increase in shares ahead of its fiscal second-quarter results, with analysts expecting earnings of $2.66 per share and revenue of $7.68 billion, reflecting sustained optimism about semiconductor equipment demand.
See More
Doximity Shares Plunge 25% to Lowest Level Since IPO
- Disappointing Guidance: Doximity (DOCS) experienced a ~25% drop in stock price after its Q4 fiscal 2026 guidance failed to meet Wall Street expectations, reaching its lowest level since its 2021 IPO, indicating market concerns over future growth.
- Analyst Downgrade: KeyBanc Capital Markets downgraded Doximity from Overweight to Sector Weight, projecting fiscal 2027 revenue between $664 million and $676 million due to the AI Search product missing the sales peak, highlighting a lack of catalysts and increased downside risk.
- Market Share Challenges: Analyst Scott Schoenhaus noted that Doximity is not gaining market share this year as budget managers prefer cutting-edge AI or low-cost options over its premium offerings, reflecting a more competitive market landscape.
- AI Investment Year: While Doximity is catching up in AI, the anticipated revenue from the AI Search product is not expected until the second half of 2027, putting pressure on the company's growth outlook and indicating insufficient competitiveness in the digital advertising market.
See More
Doximity Shares Drop 24% After Disappointing Q4 Earnings Report
- Disappointing Performance: Doximity's Q4 sales rose by 5% and free cash flow (FCF) increased by 11%, yet the company fell short of Wall Street's earnings expectations, resulting in a 24% drop in share price as of Thursday morning.
- Conservative Future Outlook: Management's full-year revenue growth guidance for 2027 is only 3% to 5%, coupled with a declining adjusted EBITDA margin, indicating significant growth challenges ahead for the company.
- Increased AI Investment: Despite profitability pressures, Doximity is ramping up investments in AI products, which are expected to further impact margins; however, the company is making promising strides in technology adoption.
- Stable Market Position: With 85% of U.S. physicians on its network and partnerships with 20 of the top hospitals and pharmaceutical companies, Doximity's leadership remains intact, although the industry slowdown will still pose challenges.
See More
Doximity Shares Plunge 56% Amid AI Threat Concerns
- Stock Decline: Doximity's shares have plummeted 56% following its fourth-quarter earnings report in 2026, highlighting market concerns regarding the company's ability to survive the threats posed by the rise of AI technologies.
- Strong User Base: With over 85% of U.S. physicians using its platform, Doximity has established a massive network that attracts all of the top 20 pharmaceutical companies as advertising clients, underscoring its solid market position.
- AI Tool Adoption: In the fourth quarter, approximately 50% of Doximity's 800,000 active prescribers utilized AI tools within its workflow solutions, indicating the company's proactive integration of AI despite competitive pressures in the market.
- Optimistic Investment Outlook: Despite rising costs during its
See More
Doximity Faces AI Threats but Strong Ecosystem Remains
- Market Concerns Over AI: The market's anxiety regarding AI potentially replacing Doximity's medical solutions has intensified, resulting in a staggering 56% drop in stock price in 2026, indicating investor caution about the company's future viability.
- Robust Customer Base: Doximity boasts a strong ecosystem with over 85% of U.S. physicians using its platform, and all top 20 pharmaceutical companies as advertising clients, providing a stable revenue stream for the company.
- AI Tool Adoption: In Q4, approximately 50% of active prescribers utilized AI tools within Doximity's workflow solutions, showcasing the company's potential in AI integration, although this has also led to a dip in margins.
- Investment Value Analysis: With a free cash flow multiple of just 15 times and a cash balance of $700 million, Doximity is still viewed as a top buy despite AI threats, especially as the pharmaceutical advertising sector is expected to rebound.
See More
Doximity Faces Securities Fraud Investigation
- Financial Performance Warning: Doximity announced its Q4 and FY 2026 results, projecting full-year revenue between $664 million and $676 million, falling short of market expectations of $687.04 million, indicating growth challenges for the company.
- AI Cost Impact: Management highlighted that AI compute costs negatively affected gross margins, with the VP of investor relations mentioning this issue, while CEO Jeff Tangney warned that increased AI investments would pressure near-term profitability, reflecting the risks associated with tech investments.
- Significant Stock Decline: Following the earnings report, Doximity's stock price plummeted by $5.38, or 23%, closing at $18.01 per share on May 14, 2026, signaling market concerns regarding the company's outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Doximity and its executives engaged in securities fraud or other unlawful practices, advising investors to contact the firm for more information, indicating potential legal risks for the company.
See More
Bitcoin-Linked Stocks Rise as Starbucks Gets Upgrade
- Bitcoin-Linked Stocks Rise: Bitcoin rose 2% as the Senate Banking Committee discussed a regulatory framework for cryptocurrencies, with Coinbase shares jumping nearly 9%, indicating growing market confidence that could drive future growth for related companies.
- Starbucks Upgrade: TD Cowen upgraded Starbucks from hold to buy, raising its price target from $106 to $120, with analysts noting multiple positive sales drivers in a strong market backdrop, suggesting improved performance ahead.
- Ford Stock Surge: Ford shares rose 7%, adding to a 13% gain from Wednesday, as Morgan Stanley highlighted its energy storage business and partnership with CATL, projecting a $3 billion incremental revenue opportunity for Ford's Model e segment.
- Applied Materials Earnings Outlook: Applied Materials saw a 2% increase in shares ahead of its fiscal second-quarter results, with analysts expecting earnings of $2.66 per share and revenue of $7.68 billion, reflecting sustained optimism about semiconductor equipment demand.
See More
Doximity Shares Plunge 25% to Lowest Level Since IPO
- Disappointing Guidance: Doximity (DOCS) experienced a ~25% drop in stock price after its Q4 fiscal 2026 guidance failed to meet Wall Street expectations, reaching its lowest level since its 2021 IPO, indicating market concerns over future growth.
- Analyst Downgrade: KeyBanc Capital Markets downgraded Doximity from Overweight to Sector Weight, projecting fiscal 2027 revenue between $664 million and $676 million due to the AI Search product missing the sales peak, highlighting a lack of catalysts and increased downside risk.
- Market Share Challenges: Analyst Scott Schoenhaus noted that Doximity is not gaining market share this year as budget managers prefer cutting-edge AI or low-cost options over its premium offerings, reflecting a more competitive market landscape.
- AI Investment Year: While Doximity is catching up in AI, the anticipated revenue from the AI Search product is not expected until the second half of 2027, putting pressure on the company's growth outlook and indicating insufficient competitiveness in the digital advertising market.
See More
Doximity Shares Drop 24% After Disappointing Q4 Earnings Report
- Disappointing Performance: Doximity's Q4 sales rose by 5% and free cash flow (FCF) increased by 11%, yet the company fell short of Wall Street's earnings expectations, resulting in a 24% drop in share price as of Thursday morning.
- Conservative Future Outlook: Management's full-year revenue growth guidance for 2027 is only 3% to 5%, coupled with a declining adjusted EBITDA margin, indicating significant growth challenges ahead for the company.
- Increased AI Investment: Despite profitability pressures, Doximity is ramping up investments in AI products, which are expected to further impact margins; however, the company is making promising strides in technology adoption.
- Stable Market Position: With 85% of U.S. physicians on its network and partnerships with 20 of the top hospitals and pharmaceutical companies, Doximity's leadership remains intact, although the industry slowdown will still pose challenges.
See More
